Research and Development Payments. (a) Within ten (10) business days after the Effective Date, Roche shall make a payment to Pharmasset of [***]. This upfront payment represents reimbursement of Pharmasset’s research and development expenses relating to its HCV research program, which were incurred by Pharmasset prior to the Effective Date or, except with respect to payments otherwise contemplated by this Agreement to be made to Pharmasset, are incurred by Pharmasset after the Effective Date through and including December 31, 2004.
Research and Development Payments. Eurobiotech agrees to pay SRI a further $50,000 within 90 days of signing the Co-Development Agreement to be used for research and development to be conducted at SRI's laboratories with respect to the use of 2'-fluoro-2-halo substituted purine nucleoside(s) for therapeutic indications other than cancer. The research and development program will be mutually agreed upon by the parties and funding will begin no later than thirty (30) days after such agreement or within ninety (90) days of the effective date of the Co-Development Agreement, whichever date is earlier. It is not intended that the sum defined in this paragraph shall be the total cost of the research and development program for therapeutic indications other than cancer.
Research and Development Payments. 2.5.2.1 For each of the three fiscal years beginning March 1, 1997, 1998 and 1999 and IntelliGene shall pay RPI [ ] per year, payable in quarterly installments in advance, for research support as agreed by the parties to advance commercialization of Product and Licensed Services and for access to RPI's scientists, including consultants.
Research and Development Payments. (a) Subject to the terms and conditions set forth in this Section 8.4, Takeda agrees to pay BioNumerik up to the following maximum annual Research and Development Payments in the following calendar years to develop the Product for the Territory: 2005 2006 2007 2008 2009 Total ----------------- ------------------- ----------- -------------- -------------- ------------------ Thirty million US Thirty-five million Thirty-five Thirty million Eight million One hundred dollars (US US dollars million US US dollars (US US dollars (US thirty-eight $30,000,000) (US$35,000,000) dollars (US $30,000,000) $8,000,000) million US dollars $35,000,000) (US $138,000,000)
Research and Development Payments. Pursuant to Section 5.3, Context shall make payments (the “Context R&D Payments”) to Integral for activities to be undertaken by Integral under the Research and Development Plan. The Research and Development Payments shall cover all reasonable expenses to be incurred by Integral pursuant to the Research and Development Plan, which shall include Integral’s out-of-pocket expenses, purchases, and contracted services, as well as all internal and external contracted services and FTE Costs (the “Expenses”). Unless mutually agreed by the Parties, the Expenses shall not exceed the amount pre-approved and budgeted in the Research and Development Plan (the “Budget”), which may be amended from time to time by the Joint Research Committee.
Research and Development Payments. In partial consideration of the rights granted Wyeth-Ayerst under this Agreement, Wyeth-Ayerst shall pay ArQule the following amounts within ***** days after each occurrence of the following milestones: Payment for Royalty- Bearing Products Events ---------------- ------ ***** ***** ***** ***** ***** ***** ***** ***** * Confidential Treatment has been requested for the marked portions of this agreement.
Research and Development Payments. (a) Roche shall reimburse to ArQule a total of * dollars ($*) for the ArQule Program research and development costs and expenses incurred by ArQule on or before the end of the Option Term. These payments shall be non-refundable and non-creditable, and shall be due and payable, except as provided in Section 4.1(b), as follows:
Research and Development Payments. In partial consideration of the rights granted Wyeth-Ayerst under this Agreement, Wyeth-Ayerst shall pay ArQule the following amounts within * days after each occurrence of the following milestones: Payment for Royalty- Bearing Products Events $* For each Royalty-Bearing Product upon * $* * for each Royalty-Bearing Product Payment for Royalty- Bearing Products Events $* * as defined below $* * for each Royalty-Bearing Product $* * for each Royalty-Bearing Product. $* * for each Royalty-Bearing Product. $* * for the first additional indication only for each Royalty-Bearing Product. $* * for the first additional indication only for each Royalty-Bearing Product. As used in this Section 8.2, * means the decision of the Wyeth-Ayerst Research Operations Committee or its equivalent to *. At least *. * will measure appropriate endpoints. An * must have a * without *. Cost of goods must remain commercially reasonable to proceed with development. Such Research and Development payments shall be non-refundable and shall not be credited against royalties payable to ArQule under this Agreement. Research and Development payments shall be paid for the first occurrence of each Event listed above with respect to each Royalty-Bearing Product. Wyeth-Ayerst shall promptly notify ArQule of each occurrence of any of the foregoing Events.
Research and Development Payments. Licensee shall pay Tepha a total sum of * to support Tepha's research and developments efforts and completion of filing of the Device Master File for the Polymer with the FDA, which said Research and Development payments shall be deemed earned and due as follows: * which the parties acknowledge has been paid prior to the Effective Date; and * earned and due at the rate of * per month beginning January 1, 2003; and * upon the completion of filing of the Device Master File with the FDA. Such final * payment shall be subject to a reduction of * for each month that the filing is delayed beyond December 31, 2003; provided, however, such date shall be extended if the implantation studies shall not be completed by November 30, 2003. Such extension shall equal the additional period of time reasonably necessary for such studies to be completed, plus one month.
Research and Development Payments. To provide ongoing support for Product Development through the first full calendar quarter after submission of the BLA in the United States (the "Final Quarter"), and subject to the exceptions described in this section below, Paladin shall pay Connetics according to the following schedule: Amount Due Due Date [*] [*] Notwithstanding the foregoing payment schedule, Paladin shall not be required to pay Connetics more than [*] of the amount that Medeva PLC pays to Connetics for any given calendar quarter pursuant to Section 4.1.3 of the Medeva Agreement. Should the Final Quarter conclude before a Due Date, then Paladin will make one final payment to Connetics in support of Product Development in lieu of any further "Amounts Due" listed above. The final payment shall be an amount equal to the next "Amount Due" and shall be payable on the corresponding Due * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
